Ras

Cat. No.

A40982

CAS No.

3077480-59-9

Z52

Z52 is a potent Ras protein inhibitor that targets the Ras signaling pathway, which is frequently dysregulated in various cancers. This compound exhibits significant biological activity in inhibiting Ras-driven tumorigenesis and may serve as a valuable tool for cancer research, particularly in investigating the mechanisms underlying pancreatic cancer. Its utility in studying Ras-mediated cellular processes makes it an important reagent for advancing therapeutic strategies against Ras-dependent malignancies.

Cat. No.

A41062

CAS No.

3077480-61-3

Z56

Z56 is a selective inhibitor of Ras proteins, targeting key signaling pathways involved in cellular growth and proliferation. It demonstrates potent biological activity in modulating Ras-dependent signaling, making it a valuable tool for cancer research, particularly in the study of pancreatic cancer. Researchers can utilize Z56 to explore novel therapeutic strategies and investigate the mechanistic roles of Ras in tumorigenesis.

Cat. No.

A41461

CAS No.

3077488-80-0

Z52-L16

Z52-L16 is a Ras inhibitor that functions through the modulation of key signaling pathways involved in tumorigenesis. This drug-linker conjugate is specifically designed for antibody-drug conjugate (ADC) applications, facilitating targeted delivery in cancer research. Z52-L16 is particularly relevant for studies focused on pancreatic cancer, providing a valuable tool for investigating therapeutic strategies against Ras-driven malignancies.

Cat. No.

A41863

CAS No.

2088485-33-8

Deltasonamide 1

Deltasonamide 1 is a potent inhibitor of the PDE6δ-KRas interaction, exhibiting a dissociation constant (KD) of 203 pM. This compound effectively disrupts the function of the KRas signaling pathway, making it a valuable tool for investigating tumor biology and related therapeutic strategies. Deltasonamide 1 holds promise for advancing research in cancer treatment and understanding related pathophysiological mechanisms.

Cat. No.

A41886

CAS No.

1613404-76-4

Deltarasin hydrochloride

Deltarasin hydrochloride is a potent inhibitor of the interaction between KRAS and PDEδ, exhibiting a binding affinity (Kd) of 38 nM for purified PDEδ. This compound is crucial for research applications focused on targeting KRAS-driven oncogenesis, primarily in cancer studies. By disrupting this interaction, Deltarasin hydrochloride facilitates investigations into therapeutic strategies aimed at KRAS mutations and their downstream signaling pathways.

Cat. No.

A41994

CAS No.

2235358-73-1

Deltasonamide 1 TFA

Deltasonamide 1 TFA is a potent inhibitor of the PDE6δ-KRas interaction, exhibiting a binding affinity with a KD of 203 pM. This compound is valuable in research focused on cancer biology, particularly in the study of tumor progression and metastasis. Its ability to disrupt the PDE6δ-KRas axis makes it a useful tool for investigating the underlying mechanisms of KRas-driven malignancies.

Cat. No.

A42254

CAS No.

2540915-70-4

NHTD

NHTD is a selective inhibitor of KRAS-PDEδ, targeting the prenyl-binding pocket of PDEδ and modulating the cellular localization of KRAS. This action effectively inhibits the proliferation of KRAS-mutant cancer cells and promotes apoptosis. NHTD is a valuable tool for investigations into KRAS-driven non-small cell lung cancer (NSCLC) and related oncology research.

Cat. No.

A47518

CAS No.

102042-09-1

21-Hydroxyoligomycin A

21-Hydroxyoligomycin A is a potent inhibitor of K-Ras plasma membrane localization, exhibiting an IC50 value of 4.82 nM. This compound demonstrates cytotoxic effects and is derived from the bacterium Streptomyces. It is useful for studying K-Ras signaling pathways and their implications in cancer research.

Cat. No.

A53056

CAS No.

2310304-72-2

Rac1-IN-6

Rac1-IN-6 is a selective inhibitor of the Rac1 protein, primarily targeting its activation induced by the Escherichia coli CNF1 toxin. This compound exhibits significant antimalarial activity, demonstrating growth suppression of chloroquine-sensitive Plasmodium falciparum D10 with an IC50 of 76.0 nM, as well as chloroquine-resistant Plasmodium falciparum W2 with an IC50 of 236.6 nM. Rac1-IN-6 is valuable for research into Rac1-related signaling pathways and malaria therapies.

Cat. No.

A56864

CAS No.

2649788-46-3

KRAS G12C inhibitor 67

KRAS G12C Inhibitor 67 is an orally bioavailable compound that selectively targets the KRAS G12C mutant. It effectively inhibits phosphorylated ERK (pERK) and active KRAS, leading to reduced proliferation in various tumor cell lines harboring the KRAS G12C mutation. This inhibitor demonstrates significant anticancer activity against several types of malignancies, including esophageal, bladder, colorectal, lung, and pancreatic cancers, making it a valuable tool for cancer research and therapeutic development.

Cat. No.

A56870

CAS No.

2653994-10-4

(S)-Opnurasib

Synonyms: (S)-JDQ-443; (S)-NVP-JDQ443

(S)-Opnurasib is a potent and selective covalent inhibitor targeting KRAS G12C. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research focused on KRAS-driven malignancies. Its oral bioavailability and specificity for the mutant KRAS G12C offer promising avenues for therapeutic exploration and development in oncology.

Cat. No.

A56873

CAS No.

2653201-38-6

(Rac)-Opnurasib

Synonyms: (Rac)-JDQ-443; (Rac)-NVP-JDQ443

(Rac)-Opnurasib is a potent and selective covalent inhibitor of KRAS G12C. This compound demonstrates significant antitumor activity and is utilized in research focused on cancer therapies targeting KRAS mutations. Its oral bioavailability makes it an attractive candidate for preclinical studies aimed at evaluating the therapeutic potential of KRAS inhibition in oncological applications.

Cat. No.

A56874

CAS No.

2375482-34-9

KRAS-IN-56

KRAS-IN-56 is a selective KRAS inhibitor that targets the interaction between GTP-bound KRAS and SOS1, demonstrating an EC50 of 33 μM. This compound effectively reduces phosphorylated ERK (p-ERK) levels, making it a valuable tool for studying MAPK signaling pathways. KRAS-IN-56 is particularly relevant for research applications involving lung cancer and other KRAS-driven malignancies.

Cat. No.

A56880

CAS No.

3059496-56-6

KRAS inhibitor-40

KRAS inhibitor-40 is a selective inhibitor targeting the KRAS G12C-BRAF complex. By inhibiting ERK phosphorylation within the KRAS downstream signaling pathway, this compound effectively suppresses tumor cell proliferation across various KRAS mutation types. KRAS inhibitor-40 demonstrates notable antitumor activity, making it a valuable tool for cancer research and therapeutic development.

Cat. No.

A56884

CAS No.

3084918-70-4

KRAS-IN-54

KRAS-IN-54 is a macrocyclic inhibitor targeting KRAS, specifically designed to disrupt the activity of KRASG12D and KRASG13D mutant forms. This compound demonstrates significant effects on cell viability and phosphorylation of ERK (pERK), making it a valuable tool for studying KRAS-dependent signaling pathways. KRAS-IN-54 is applicable in research focused on various KRAS-mutant cancers, such as pancreatic adenocarcinoma, colorectal cancer, non-small cell lung cancer, and melanoma, among others.

Cat. No.

A63525

CAS No.

3024878-19-8

Eras-4001

Eras-4001 is a pan-KRAS inhibitor that demonstrates significant antitumor activity by effectively inhibiting the proliferation of both wild-type and mutant KRAS cancer cells, including variants such as KRASG12D, KRASG12V, and KRASG12C. In preclinical studies, Eras-4001 has evidenced a robust ability to suppress tumor growth in xenograft mouse models, such as GP2D and Panc0403, making it a valuable tool for investigating KRAS-driven malignancies and potential therapeutic strategies in cancer research.

Cat. No.

A63528

CAS No.

1222513-26-9

CID44216842

Synonyms: Cdc42-IN-1

CID44216842 is a selective inhibitor of the small GTPase Cdc42, acting primarily by disrupting its guanine nucleotide binding. It demonstrates potent inhibitory activity with EC50 values of 1.0 μM and 1.2 μM for wild-type Cdc42 and the Cdc42Q61L mutant, respectively, in GTP binding assays, and 0.3 μM and 0.5 μM in GDP binding assays. This compound is suitable for use as a molecular probe in studies related to Cdc42 signaling pathways and its role in cellular processes such as cytoskeletal dynamics and cell migration.

Cat. No.

A63529

CAS No.

2958627-18-2

AZD0022

AZD0022 is a selective and orally active inhibitor of the KRAS G12D mutant protein. It effectively disrupts the KRAS signaling pathway, demonstrating suppression of tumor growth in the GP2D xenograft model. This compound is relevant for research in cancer therapeutics, particularly for investigating KRAS-driven malignancies.

Cat. No.

A63531

CAS No.

900897-56-5

KRAS inhibitor-3

KRAS inhibitor-3 is a selective inhibitor of the KRAS protein, effectively targeting both wild-type and various oncogenic mutants, including KRAS G12C, G12D, and Q61H, with affinities ranging from 0.28 μM to 0.74 μM. This compound disrupts the interaction between KRAS and Raf, thereby influencing downstream signaling pathways critical for cell proliferation and survival. KRAS inhibitor-3 is a valuable tool for research applications focused on cancer biology and the development of targeted therapies for KRAS-driven malignancies.

Cat. No.

A63532

CAS No.

23979-41-1

l-Naproxen

Synonyms: (R)-Naproxen

l-Naproxen is an enantiomer of (S)-Naproxen, functioning as an inhibitor of Cdc42 and Rac1 with EC50 values of 96 μM and 212 μM, respectively. It exhibits anti-tumor activity in addition to its role as a nonsteroidal anti-inflammatory drug (NSAID). This compound is valuable for research applications involving cellular signaling pathways, inflammation, and cancer biology.

Cat. No.

A63533

CAS No.

708-06-5

CFL-137

CFL-137 is a potent inhibitor of KRasG12C, a pivotal mutation implicated in various cancers. This compound demonstrates significant antiproliferative activity, making it a valuable tool for studying oncogenic signaling pathways. CFL-137 holds promise for research applications focused on lung cancer and other KRas-driven malignancies.

Cat. No.

A63534

CAS No.

2578876-75-0

KRAS inhibitor-10

KRAS Inhibitor-10 is a selective inhibitor targeting RAS proteins, with a strong emphasis on KRAS variants. This orally active compound demonstrates significant anti-cancer activity, making it suitable for research applications in various malignancies, including pancreatic cancer, breast cancer, multiple myeloma, leukemia, and lung cancer. KRAS Inhibitor-10 is derived from a tetrahydroisoquinoline structure and is detailed in patent WO2021005165 A1.

Cat. No.

A63535

CAS No.

3018057-89-8

KRAS G12D-IN-29

KRAS G12D-IN-29 is a selective inhibitor targeting the KRAS G12D mutant, known for its oral bioavailability. This compound effectively disrupts downstream signaling pathways associated with KRAS G12D, leading to a reduction in tumor cell proliferation. KRAS G12D-IN-29 shows potential for research applications focused on cancers driven by the KRAS G12D mutation, including pancreatic, lung, and colorectal cancers.

Cat. No.

A63537

CAS No.

2920695-77-6

KRAS inhibitor-31

KRAS Inhibitor-31 is a potent inhibitor targeting mutant forms of the KRAS protein, specifically KRAS G12D, G12C, and G12V, with KD (SPR) values of 0.019 nM, 0.019 nM, and 0.096 nM, respectively. This compound demonstrates significant biological activity in the inhibition of KRAS-driven signaling pathways, making it a valuable tool for research in cancer biology, particularly in the study of tumors harboring KRAS mutations.

Cat. No.

A63538

CAS No.

2882825-14-9

pan-KRAS-IN-2

pan-KRAS-IN-2 is a potent pan-KRAS inhibitor with IC50 values of ≤ 10 nM against both wild-type and prevalent mutant forms of KRAS, including G12D, G12C, G12V, G12S, G12A, and Q61H, while exhibiting an IC50 > 10 μM for KRAS G13D. This compound is valuable for investigating KRAS-mediated cancers, specifically in pancreatic and colorectal cancer models, aiding in the understanding of tumor biology and potential therapeutic interventions.